162 related articles for article (PubMed ID: 31897161)
1. A novel tumor suppressing gene,
Piao XM; Jeong P; Yan C; Kim YH; Byun YJ; Xu Y; Kang HW; Seo SP; Kim WT; Lee JY; Kim IY; Moon SK; Choi YH; Cha EJ; Yun SJ; Kim WJ
Oncol Lett; 2020 Jan; 19(1):476-486. PubMed ID: 31897161
[TBL] [Abstract][Full Text] [Related]
2. Silencing ARHGAP9 correlates with the risk of breast cancer and inhibits the proliferation, migration, and invasion of breast cancer.
Wang T; Ha M
J Cell Biochem; 2018 Sep; 119(9):7747-7756. PubMed ID: 29905031
[TBL] [Abstract][Full Text] [Related]
3. Effect of Rho GTPase activating protein 9 combined with preoperative ratio of platelet distribution width to platelet count on prognosis of patients with serous ovarian cancer.
Shen Y; Xu H; Guan Z; Lv M; Qian T; Wu Y
Transl Cancer Res; 2021 Oct; 10(10):4440-4453. PubMed ID: 35116301
[TBL] [Abstract][Full Text] [Related]
4. Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer.
Shim UJ; Lee IS; Kang HW; Kim J; Kim WT; Kim IY; Ryu KH; Choi YH; Moon SK; Kim YJ; Yun SJ; Lee SC; Kim WJ
Korean J Urol; 2013 Sep; 54(9):631-7. PubMed ID: 24044099
[TBL] [Abstract][Full Text] [Related]
5.
Pignot G; Le Goux C; Vacher S; Schnitzler A; Radvanyi F; Allory Y; Lallemand F; Delongchamps NB; Zerbib M; Terris B; Damotte D; Bieche I
Oncol Lett; 2019 Oct; 18(4):3471-3480. PubMed ID: 31516565
[TBL] [Abstract][Full Text] [Related]
6. Rho GTPase Activating Protein 9 (ARHGAP9) in Human Cancers.
Song W; Chen J; Li S; Li D; Zhang Y; Zhou H; Yu W; He B; Zhang W; Li L
Recent Pat Anticancer Drug Discov; 2022; 17(1):55-65. PubMed ID: 34365932
[TBL] [Abstract][Full Text] [Related]
7. Utility of SAM68 in the progression and prognosis for bladder cancer.
Zhang Z; Yu C; Li Y; Jiang L; Zhou F
BMC Cancer; 2015 May; 15():364. PubMed ID: 25944080
[TBL] [Abstract][Full Text] [Related]
8. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
9. Comparative bioinformatics analysis of prognostic and differentially expressed genes in non-muscle and muscle invasive bladder cancer.
Silva TA; Azevedo H
J Proteomics; 2020 Oct; 229():103951. PubMed ID: 32860965
[TBL] [Abstract][Full Text] [Related]
10.
Kim K; Byun YJ; Zheng CM; Moon S; Jo SJ; Kang HW; Kim WT; Choi YH; Moon SK; Kim WJ; Piao XM; Yun SJ
Investig Clin Urol; 2024 Jan; 65(1):94-103. PubMed ID: 38197756
[TBL] [Abstract][Full Text] [Related]
11. Nested quantitative PCR approach for urinary cell-free EZH2 mRNA and its potential clinical application in bladder cancer.
Zhang X; Zhang Y; Liu X; Liu T; Li P; Du L; Yang Y; Wang L; Wang C
Int J Cancer; 2016 Oct; 139(8):1830-8. PubMed ID: 27300769
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer.
Lee MS; Lee J; Kim JH; Kim WT; Kim WJ; Ahn H; Park J
Oncotarget; 2015 Nov; 6(37):40370-84. PubMed ID: 26430961
[TBL] [Abstract][Full Text] [Related]
13. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
14. Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer.
Fang Z; Dai W; Wang X; Chen W; Shen C; Ye G; Li L
Tumour Biol; 2016 Jun; 37(6):8075-82. PubMed ID: 26715266
[TBL] [Abstract][Full Text] [Related]
15. Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non-Muscle-Invasive Bladder Cancer.
Xu Y; Kim YH; Jeong P; Piao XM; Byun YJ; Seo SP; Kang HW; Kim WT; Lee JY; Ryu DH; Choi JW; Kim IY; Moon SK; Choi YH; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2019 Jun; 17(3):e704-e711. PubMed ID: 31088707
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of ST3GAL5 is associated with muscle invasion, high grade and a poor prognosis in patients with bladder cancer.
Ouyang S; Liu JH; Ni Z; Ding GF; Wang QZ
Oncol Lett; 2020 Jul; 20(1):828-840. PubMed ID: 32566010
[TBL] [Abstract][Full Text] [Related]
17. History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.
Kayama E; Kikuchi E; Fukumoto K; Shirotake S; Miyazaki Y; Hakozaki K; Kaneko G; Yoshimine S; Tanaka N; Takahiro M; Kanai K; Oyama M; Nakajima Y; Hara S; Monma T; Oya M
Clin Genitourin Cancer; 2018 Oct; 16(5):e969-e976. PubMed ID: 29778322
[TBL] [Abstract][Full Text] [Related]
18. mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.
Le Goux C; Vacher S; Pignot G; Sibony M; Barry Delongchamps N; Terris B; Piaggio E; Zerbib M; Damotte D; Bieche I
Oncoimmunology; 2017; 6(11):e1358330. PubMed ID: 29147616
[TBL] [Abstract][Full Text] [Related]
19. Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer.
Cai Z; Chen H; Bai J; Zheng Y; Ma J; Cai X; Liu Y; Zhang K; Shou J; Gao Y
Front Oncol; 2021; 11():674933. PubMed ID: 34041036
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer.
Abdelrahman AE; Rashed HE; Elkady E; Elsebai EA; El-Azony A; Matar I
Ann Diagn Pathol; 2019 Apr; 39():42-52. PubMed ID: 30684846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
